BioSpace News Archive

Find out which biopharma companies are raking in cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

An 18-month analysis shows that median Overall Survival will be at least 18.2 months for first-line patients receiving ONCOS-102 plus chemotherapy, compared to mOS of 14.2 months or less in the chemotherapy-only control group ONCOS-102-treated patients show broad and powerful immune activation, associated with better survival outcome

Award will help to fund planned Phase Ib/IIa study of inhaled murepavadin, a novel class antibiotic for the treatment of chronic Pseudomonas aeruginosa infections in cystic fibrosis

Evotec SE announced a new multi-year drug development partnership with Rappta Therapeutics, a Finland-based biopharmaceutical company, focused on an innovative oncology target.

OMRON Healthcare Co., Ltd. announced on November 24 additional investment into AliveCor by its parent company, OMRON Corporation, as part of $65 million series E funding for the leader in AI-based personal electrocardiogram technology.

Grant protects a proprietary approach that enables luminal loading of soluble therapeutic proteins into exosomes

Ultimovacs ASA, announced that Ton Berkien will join Ultimovacs’ management team as Chief Business Officer, effective December 1, 2020.

Midatech Pharma PLC, an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to note that the latest research on MTX110 was presented by its collaborators at the recent annual meeting of the Society of Neuro-Oncology.

Pharmaceutical clinical industry report highlights factors impacting volume, cost and duration of Phase II trials

Carbamoyl phosphate synthetase I deficiency is a rare inherited disorder characterized by complete or partial lack of the carbamoyl phosphate synthetase (CPS) enzyme